Fact sheet: AXA Framlington Health

Fund information
Fund name
AXA Framlington Health Z Inc
Fund manager company
AXA IM UK
Fund type
Unit Trust
Fund managers
  • Dani Saurympersince 01/04/2015
Fund objective
The aim of this Fund is to provide long-term capital growth.
Benchmark
  • MSCI World Healthcare
Investment style
Growth
Investment method
Shares
Quick stats
1 Year return
18.7%
1 Year rank in sector
64/110
Sector
UT Specialist
Yield
0.3%
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
0.82%
Fund size
£541m (£506m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
137
Top in this sector
Fund name1 Year
Jupiter India53.3%
Neptune Russia & Gtr Rus50.2%
SF Petrhse Sm Cos Gold49.5%
F&C UK Equity Linked Inflation47.1%
Neptune Latin America46.8%
...more in UT Specialist

Performance snapshot

Holdings snapshot

  • North America68.6%
    Europe ex UK14.8%
    UK10.1%
    Money Market3%
    Japan2.6%
  • Pharmaceuticals29.8%
    Biotechnology/Medical25.6%
    Health Care19.3%
    Healthcare & Medical Products17.8%
    Money Market3%
  • North American Equities68.6%
    Europe ex UK Equities14.8%
    UK Equities10.1%
    Money Market3%
    Japanese Equities2.6%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund-0.5%-1.2%5.9%18.7%58.9%131.4%
Sector0.7%0.6%7.3%20.4%21.4%39.8%
Rank within sector85 / 11286 / 11074 / 11064 / 11010 / 1037 / 86
Quartile4th4th3rd3rd1st1st
Calendar performance
 YTD - 20172016201520142013
Fund4.6%7.8%12.2%29.6%34.6%
Sector4.2%22.7%-4.5%1.2%4.5%
Rank within sector55 / 11080 / 1095 / 1055 / 1012 / 91
Quartile2nd3rd1st1st1st
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
11.88
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
0.79
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
1
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
14.52
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
12.37
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
0.75
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.29
Price movement
52 week high127.8
52 week low98.99
Current bid price-
Current offer price-
Current mid price119.6
Region
1North America68.58%
2Europe ex UK14.8%
3UK10.08%
4Money Market2.98%
5Japan2.62%
6Global Emerging Markets0.94%
Industry sector
1Pharmaceuticals29.83%
2Biotechnology/Medical25.62%
3Health Care19.34%
4Healthcare & Medical Products17.76%
5Money Market2.98%
6Hospital1.86%
7Food & Drug Retailers1.38%
8Conglomerates1.23%
Asset type
1North American Equities68.58%
2Europe ex UK Equities14.8%
3UK Equities10.08%
4Money Market2.98%
5Japanese Equities2.62%
6Global Emerging Market Equities0.94%
Individual holdings
1ROCHE HLDG AG5.2%
2GLAXOSMITHKLINE4.9%
3UNITEDHEALTH GROUP INC4.6%
4ALLERGAN PLC4.5%
5CELGENE CORP4.2%
6GILEAD SCIENCES INC3.7%
7MEDTRONIC INC3.6%
8LILLY (ELI) & CO2.9%
9SHIRE PLC2.5%
Management
Fund manager group
AXA Investment Managers
Fund manager company
AXA IM UK
Fund type
Unit Trust
Fund objective
The aim of this Fund is to provide long-term capital growth.
Benchmark
  • MSCI World Healthcare
Investment style
Growth
Investment method
Shares
Fund managers
NameSinceBiography
Dani Saurymper01/04/2015Dani Saurymper joined AXA IM in April 2015 as Portfolio Manager for the AXA Framlington Health funds. Dani has 14 years’ experience. Prior to joining AXA IM in April 2015 as Portfolio Manager, he was a senior equity research analyst covering European Healthcare at Barclays Capital. Dani started his career at Goldman Sachs as a senior pharmaceutical analyst covering European Pharmaceuticals, before moving to Nomura as a sector specialist covering global healthcare Dani graduated from Leeds University with a BSc in Management Studies and Pharmacology and holds an MSc in International Business from the Manchester School of Management, UMIST.
Compliance
Transparent for Swiss Tax, IA Recognised, UCITS IV Compliant, UCITS V Compliant
Domicile
No data available.
Fund for sale in
Switzerland, United Kingdom
AXA Framlington Health R Acc
Initial charge5.5%
Annual charge1.5%
Min single investment£1,000
Min regular saving£100
Available in ISAYes
Ongoing charge (OCF)1.57%
Total expense ratio (TER)1.58%
Bid price-
Offer price-
Mid price1827
CurrencyGBX
Price updated25/05/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFR45
AXA Framlington Health R Inc
Initial charge5.5%
Annual charge1.5%
Min single investment£1,000
Min regular saving£100
Available in ISAYes
Ongoing charge (OCF)1.57%
Total expense ratio (TER)1.58%
Bid price-
Offer price-
Mid price1827
CurrencyGBX
Price updated25/05/2017
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeFR44
AXA Framlington Health Z Acc
Initial charge-
Annual charge0.75%
Min single investment£100,000
Min regular saving£5,000
Available in ISANo
Ongoing charge (OCF)0.82%
Total expense ratio (TER)0.83%
Bid price-
Offer price-
Mid price238.6
CurrencyGBX
Price updated25/05/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi code11VI
AXA Framlington Health Z Inc
Initial charge-
Annual charge0.75%
Min single investment£100,000
Min regular saving£5,000
Available in ISANo
Ongoing charge (OCF)0.82%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price119.6
CurrencyGBX
Price updated25/05/2017
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeM4KM
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.